These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 9871575)
1. Molecular dynamics simulations of the structure of aldose reductase complexed with the inhibitor tolrestat. Rastelli G; Costantino L Bioorg Med Chem Lett; 1998 Mar; 8(6):641-6. PubMed ID: 9871575 [TBL] [Abstract][Full Text] [Related]
2. Hydrogen bonding interactions between aldose reductase complexed with NADP(H) and inhibitor tolrestat studied by molecular dynamics simulations and binding assay. Lee YS; Hodoscek M; Kador PF; Sugiyama K Chem Biol Interact; 2003 Feb; 143-144():307-16. PubMed ID: 12604217 [TBL] [Abstract][Full Text] [Related]
3. Studies on the inhibitor-binding site of porcine aldehyde reductase: crystal structure of the holoenzyme-inhibitor ternary complex. el-Kabbani O; Carper DA; McGowan MH; Devedjiev Y; Rees-Milton KJ; Flynn TG Proteins; 1997 Oct; 29(2):186-92. PubMed ID: 9329083 [TBL] [Abstract][Full Text] [Related]
4. Rotamers of tolrestat and their binding mode to aldose reductase. Lee YS; Sugiyama K; Kador PF Adv Exp Med Biol; 1999; 463():465-72. PubMed ID: 10352720 [No Abstract] [Full Text] [Related]
5. Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex. Sugiyama K; Chen Z; Lee YS; Kador PF Biochem Pharmacol; 2000 Feb; 59(4):329-36. PubMed ID: 10644040 [TBL] [Abstract][Full Text] [Related]
6. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations. Sotriffer CA; Krämer O; Klebe G Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486 [TBL] [Abstract][Full Text] [Related]
7. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group. Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231 [TBL] [Abstract][Full Text] [Related]
8. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Urzhumtsev A; Tête-Favier F; Mitschler A; Barbanton J; Barth P; Urzhumtseva L; Biellmann JF; Podjarny A; Moras D Structure; 1997 May; 5(5):601-12. PubMed ID: 9195881 [TBL] [Abstract][Full Text] [Related]
9. Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Carbone V; Zhao HT; Chung R; Endo S; Hara A; El-Kabbani O Bioorg Med Chem; 2009 Feb; 17(3):1244-50. PubMed ID: 19121944 [TBL] [Abstract][Full Text] [Related]
10. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227 [TBL] [Abstract][Full Text] [Related]
11. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme. El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717 [TBL] [Abstract][Full Text] [Related]
12. Evidence for a novel binding site conformer of aldose reductase in ligand-bound state. Steuber H; Zentgraf M; La Motta C; Sartini S; Heine A; Klebe G J Mol Biol; 2007 May; 369(1):186-97. PubMed ID: 17418233 [TBL] [Abstract][Full Text] [Related]
13. Mechanism of human aldehyde reductase: characterization of the active site pocket. Barski OA; Gabbay KH; Grimshaw CE; Bohren KM Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785 [TBL] [Abstract][Full Text] [Related]
14. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis. Hohman TC; El-Kabbani O; Malamas MS; Lai K; Putilina T; McGowan MH; Wane YQ; Carper DA Eur J Biochem; 1998 Sep; 256(2):310-6. PubMed ID: 9760169 [TBL] [Abstract][Full Text] [Related]
15. Nitrophenyl derivatives as aldose reductase inhibitors. Costantino L; Ferrari AM; Gamberini MC; Rastelli G Bioorg Med Chem; 2002 Dec; 10(12):3923-31. PubMed ID: 12413844 [TBL] [Abstract][Full Text] [Related]
16. Docking and molecular dynamics study on the inhibitory activity of coumarins on aldose reductase. Wang Z; Ling B; Zhang R; Liu Y J Phys Chem B; 2008 Aug; 112(32):10033-40. PubMed ID: 18637681 [TBL] [Abstract][Full Text] [Related]
17. The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48. Ruiz F; Hazemann I; Mitschler A; Joachimiak A; Schneider T; Karplus M; Podjarny A Acta Crystallogr D Biol Crystallogr; 2004 Aug; 60(Pt 8):1347-54. PubMed ID: 15272156 [TBL] [Abstract][Full Text] [Related]
18. Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase. Wang Z; Ling B; Zhang R; Suo Y; Liu Y; Yu Z; Liu C J Mol Graph Model; 2009 Sep; 28(2):162-9. PubMed ID: 19616461 [TBL] [Abstract][Full Text] [Related]
19. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Lee YS; Chen Z; Kador PF Bioorg Med Chem; 1998 Oct; 6(10):1811-9. PubMed ID: 9839011 [TBL] [Abstract][Full Text] [Related]
20. Tolrestat acts atypically as a competitive inhibitor of the thermostable aldo-keto reductase Tm1743 from Thermotoga maritima. Zhang C; Min Z; Liu X; Wang C; Wang Z; Shen J; Tang W; Zhang X; Liu D; Xu X FEBS Lett; 2020 Feb; 594(3):564-580. PubMed ID: 31573681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]